Verified peer comparison

ABT vs BSX

Abbott Laboratories compared with Boston Scientific Corporation. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABT

Abbott Laboratories

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

BSX

Boston Scientific Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABT: Health Care Equipment

BSX: Health Care Equipment

Upside lens

ABT: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

BSX: FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications. A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

Risk lens

ABT: Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

BSX: Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms. Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio. Large rivals and new technologies can pressure pricing, physician loyalty and market share.

Verified sources

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified